Table 2.

Treatment Response

HCV RNA, undetectable*	HCV genotype 1b			HCV genotype 1a	HCV genotype 2a/2b
	RAV (−)		RAV (+) Y93H
	DCV and ASV		LDV/SOF	LDV/SOF	SOF and RBV
	Naïve (n=11)	Experienced (n=7)	Naïve and experienced (n=3)	Naïve and experienced (n=5)	Naïve and experienced (n=4)
During treatment
Week 4	11 (100)	7 (100)	3 (100)	5 (100)	4 (100)
Week12	10 (90.9)	6 (85.7)	3 (100)	5 (100)	4 (100)
Week 24	10 (90.9)	6 (85.7)	-	-	-
Post treatment
Week 4	10 (90.9)	6 (85.7)	3 (100)	5 (100)	4 (100)
Week 12	10 (90.9)	6 (85.7)	3 (100)	5 (100)	4 (100)
Virologic failure
On treatment	1 (9.1)†	1 (14.3)‡	-	-	-
Relapse	-	-	-	-	-

Data are presented as number (%).

HCV, hepatitis C virus; RAV, resistance-associated variant; DCV, daclatasvir; ASV, asunaprevir; LDV/SOF, ledipasvir/sofosbuvir; RBV, ribavirin.

^*The lower limit of detection for the HCV RNA test is 15 IU/mL;

^†This patient experienced viral breakthrough without RAV at 12 weeks;

^‡This patient experienced viral breakthrough with RAV (L31M, Y93H) at 12 weeks.